Powerful biology,
transformative impact.

Target & Indication

Aldafermin is an engineered variant of the human hormone FGF19, which NGM is developing as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that irreparably damages bile ducts, leading to bile acid dysregulation, which, ultimately, results in serious liver damage. There are currently no FDA-approved therapies for PSC.

Target & Indication

Hyperemesis Gravidarum (HG), a rare, debilitating condition of pregnancy, is characterized by intractable nausea and vomiting, which can be as frequent as 10 to 15 times per day and results in dehydration, debility, weight loss and malnutrition. HG has a significant physical and psychosocial impact on patients and leads to overall higher rates of fetal loss and termination, preeclampsia, preterm birth, low birth weight, fetal malnutrition, maternal depression, and in some cases, suicidal thoughts. HG is the leading cause of hospitalization in early pregnancy and typically recurs in subsequent pregnancies. There are no approved therapies that target the underlying cause of HG.

Although GDF15 is a hormone that everyone produces, levels of GDF15 are higher in pregnant women and can be even higher in women with HG. The extremely high levels of GDF15 are believed to cause the nausea and vomiting that are hallmarks of HG. NGM120 is an antibody designed to bind to the receptor (known as GFRAL) for GDF15. This binding blocks the interaction of GDF15 with GFRAL, which, in turn, inhibits the activity of GDF15, potentially alleviating HG symptoms.

Target & Indication

Defined by >5% weight loss, cachexia is a complex, multifactorial, multi-organ complication of cancer and several other chronic diseases. 80% of advanced cancer patients are cachectic, and 30% of cancer deaths list cachexia as the primary cause. Cachexia may be a key factor for cancer treatments being ineffective or intolerable to patients.

GDF15 is a hormone that everyone produces, but elevated levels of GDF15 have been identified as the top risk factor associated with cachexia. The GDF15 pathway has been clinically validated as a potential therapeutic approach for patients with this condition. There are no approved therapies for treating cancer cachexia in the US or Europe.

NGM120 is an antibody designed to bind to the receptor (known as GFRAL) for GDF15. This binding blocks the interaction of GDF15 with GFRAL, which, in turn, inhibits the activity of GDF15. Thus, NGM120 has the potential to be a novel treatment targeting an underlying cause of cancer cachexia.

Target & Indication

A novel dual antagonist antibody inhibiting ILT2 and ILT4, NGM707 is being advanced by NGM with the goal of improving patient immune responses to tumors.

Target & Indication

NGM831 is a novel antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other cognate ligands, and NGM438 is a novel antagonist antibody developed to inhibit Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), both for the treatment of advanced solid tumors.